论文部分内容阅读
目的前瞻性地探索18-氟脱氧葡萄糖-正电子发射计算机断层扫描(18FDG-PET)的早期代谢疗效与RECIST标准评价的非小细胞肺癌(NSCLC)化疗最佳客观疗效的关系。方法初治不可切除的局部晚期和晚期NSCLC患者前瞻性入组,行含铂双药方案全身化疗。按RECIST标准和SUV值标准(2周期化疗后SUV值下降>30%)互为盲法分别评价肿瘤客观疗效。用配对计数资料的χ2检验和κ系数检验比较2周期后18FDG-PET代谢缓解与RECIST标准的最佳客观疗效是否具有一致性(SPSS13.0)。结果不可切除的局部晚期9例,晚期46例。18FDG-PET代谢缓解与按RECIST标准评价的最佳客观疗效具有明显的一致性(P<0.001)。18FDG-PET预测NSCLC化疗最佳客观疗效的敏感性、特异性、准确性、阳性预测值和阴性预测值分别是95%、67%、78%、66%和96%。结论18FDG-PET可以预测局部晚期和晚期NSCLC化疗的最佳客观疗效。
Objective To prospectively explore the relationship between the early objective of 18-fluorodeoxyglucose-positron emission computed tomography (18FDG-PET) and the objective and objective evaluation of RECIST standard non-small cell lung cancer (NSCLC) chemotherapy. Methods The patients with locally advanced unresectable and advanced non-small cell lung cancer (NSCLC) who were unresectable were prospectively enrolled and treated with platinum-based chemotherapy. According to RECIST standard and SUV value standard (SUV value decreased more than 30% after 2 cycles of chemotherapy), we evaluated the objective tumor effect separately. The paired count dataχ2 test and kappa coefficient test to compare the 2 cycles of 18FDG-PET metabolic response and RECIST standard best objective efficacy is consistent (SPSS13.0). The results of unresectable locally advanced in 9 cases, 46 cases of late. 18FDG-PET Metabolic Relief Consistent with the best objective response to RECIST criteria (P <0.001). The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 18FDG-PET for predicting the best objective response to NSCLC chemotherapy were 95%, 67%, 78%, 66%, and 96%, respectively. Conclusion 18FDG-PET can predict the best objective effect of locally advanced and advanced NSCLC chemotherapy.